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Abstract
Background: The biology of hepatic epithelial haemangioendothelioma (HEHE) is variable, lying inter-
mediate to haemangioma and angiosarcoma. Treatments vary owing to the rarity of the disease and
frequent misdiagnosis.
Methods: Between 1989 and 2013, patients retrospectively identified with HEHE from a single academic
cancer centre were analysed to evaluate clinicopathological factors and initial treatment regimens asso-
ciated with survival.
Results: Fifty patients with confirmed HEHE had a median follow-up of 51 months (range 1–322). There
was no difference in 5-year survival between patients presenting with unilateral compared with bilateral
hepatic disease (51.4% versus 80.7%, respectively; P = 0.1), localized compared with metastatic disease
(69% versus 78.3%, respectively; P = 0.7) or an initial treatment regimen of Surgery, Chemotherapy/
Embolization or Observation alone (83.3% versus 71.3% versus 72.4%, respectively; P = 0.9). However,
5-year survival for patients treated with chemotherapy at any point during their disease course was
decreased compared with those who did not receive any chemotherapy (43.6% versus 82.9%, respec-
tively; P = 0.02) and was predictive of a decreased overall survival on univariate analysis [HR 3.1 (CI
0.9–10.7), P = 0.02].
Conclusions: HEHE frequently follows an indolent course, suggesting that immediate treatment may
not be the optimal strategy. Initial observation to assess disease behaviour may better stratify treatment
options, reserving surgery for those who remain resectable/transplantable. Prospective cooperative trials
or registries may confirm this strategy.
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Introduction
Hepatic epithelioid haemangioendothelioma (HEHE) is a rare
malignant neoplasm of vascular origin. The aetiology and natural
history of HEHE is only partially understood because of its low
incidence, typically indolent growth pattern and frequent misdi-
agnosis as other tumours including cholangiocarcinoma, hepato-
cellular carcinoma and angiosarcoma.1 HEHE is thought to be a
low-grade tumour with a clinical course that lies between benign
haemangioma and aggressive angiosarcoma.1–4 The tumour most
frequently presents with pain and often there is bilateral liver
involvement and/or metastatic disease, typically to the lungs and
spine, at the time of diagnosis.1,5 Although HEHE is often diag-
nosed after evaluation for abdominal pain, it may be discovered
incidentally and in rare cases patients have presented with an
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associated Budd–Chiari syndrome, Kasabach–Merritt syndrome
or with haemorrhagic shock from a tumour rupture.6,7
The rarity of HEHE coupled with the common misdiagnosis of
the tumour has limited any randomized controlled treatment
trials and has resulted in a variety of treatment strategies ranging
from observation to chemotherapy to liver transplantation. Treat-
ment with anti-angiogenesis drugs such as thalidomide,8 immu-
notherapy with interferon α-2B,9 systemic chemotherapy,10
chemoembolization,11 or combined modality therapies have all
been utilized with varying results. Some patients who present with
diffuse liver involvement have demonstrated tumour regression
over time without any treatment.12 Furthermore, the presence of
metastatic disease has not consistently precluded surgical extirpa-
tion as selected patients with metastatic disease appear to have
benefited from surgical resection.5 Studies from Belgium and the
United States, for example, have demonstrated that orthotopic
liver transplantation can provide durable survival, even for
patients with metastatic disease.13–16 Review of the published lit-
erature on HEHE does not provide a consensus on the treatment
of this rare neoplasm and evidence exists that the survival of
patients with this tumour, once reported as a 5-year survival of
25%, may not be as poor as originally reported.17,18
Because of the inconsistent and often changing treatment strat-
egy even among individual patients, we sought to evaluate the
specific influence of the initial treatment regimen for patients
diagnosed with HEHE. Given the variable tumour biology of
HEHE, we hypothesized that a period of observation to assess
tumour biology in this generally indolent tumour may improve
selection for more appropriate patient-based treatment. In this
present study, one of the largest medical–surgical series of patients
diagnosed with HEHE to date, we assessed tumour progression
and survival based upon all initial treatment modalities that are
currently utilized in order to develop a clinical algorithm for treat-
ment of patients diagnosed with HEHE.
Methods
The collection and analysis of data associated with this study was
approved by the Institutional Review Board of the University of
Texas MD Anderson Cancer Center. From 1989 to 2013, a total of
50 patients with HEHE were identified from the cancer tumour
registry at the University of Texas MD Anderson Cancer Center
(Houston, TX, USA). Medical records were retrospectively
reviewed and clinicopathological parameters, treatments rendered
and clinical outcomes were evaluated.
The diagnosis of HEHE was guided by imaging characteristics
found on ultrasound (US), computed tomography (CT) or mag-
netic resonance imaging (MRI) and secured after a tissue sample
was obtained either by percutaneous routes or surgical means,
when the percutaneous biopsy was inconclusive or a mass was
incidentally found during a laparoscopy/laparotomy. All tumours
were examined by immunohistochemistry for the endothelial
markers CD31 and CD34.
Treatment decisions for HEHE are often made with the pre-
sumption that it has an indolent disease course or based upon the
extent of intrahepatic or metastatic disease. This prompted a
cohort analysis based on initial treatment modality as well as
survival evaluation of groups based on extent of disease. Treatment
modalities were based on three groups: those who underwent
observation only (Observation Group), patients who underwent
surgical resection (Surgical Group), and those who received
non-surgical treatment (Chemo/Embol Group) which included:
chemotherapy, immunomodulating/biological agents (interferon,
anti-angiogenesis, or COX-2 inhibition), chemoembolization,
direct tumour injection, or bland embolization. The start of the
initial treatment was defined as the date of surgery for the Surgical
group, date of chemotherapy/embolization for the Chemo/Embol
group and the date of diagnosis for the Observation group as no
specific treatment was rendered. Surveillance imaging studies
included CT scans of the chest, abdomen and pelvis, and were
performed every 6–12 months, at the discretion of the treating
physician, and reviewed for disease progression.
Statistical analyses were performed using MedCalc (v12.3)
statistical software (MedCalc Software, Mariakerke, Belgium).
Summary statistics were used to describe the clinical and
demographic characteristics of the study population and sub-
groups based on initial treatment (observation, surgical and
chemotherapy/embolization). The Kruskal–Wallis analysis of
variance was utilized to assess differences in continuous variables
between the three initial treatment groups. Differences in cat-
egorical variables between the three initial treatment groups were
assessed using Pearson’s chi-square analysis. Time to progression
(TTP) was defined as the time from institution of initial treatment
to the time of documented progression on imaging or the time of
last follow-up/death if disease progression had not been identi-
fied. Overall survival (OS) was defined as the time from initial
diagnosis of HEHE to death and was censored at the date of last
follow-up if death had not occurred. Univariate Cox’s propor-
tional hazards regression was used to model the association
between each potential prognostic factor and time to progression
(TTP) or OS. Factors shown to be predictive of TTP or OS on
univariate analysis were then evaluated using multivariate Cox’s
proportional hazards regression. The 5-year OS rate and compari-
son of proportions between treatment groups are reported for
survival data. A two-sided significance level of 0.05 and a 95%
confidence interval (CI) were used for all statistical analyses. A
P-value < 0.05 was considered statistically significant.
Results
Demographics and presentation
A total of 50 patients were identified with HEHE and histologi-
cally confirmed by immunohistochemistry with all staining posi-
tive for CD31 and CD34 and comprise the study population. The
median follow-up from diagnosis was 51 months (range 1–322).
Sixty-six per cent (n = 33) of the cohort was female with a median
age at the time of initial diagnosis of 46 years (range 18–92.1). The
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most common presenting symptom was abdominal pain (n = 28,
56%) followed by an incidental finding on abdominal imaging
(n = 8, 16%). Stratifying for the three treatment groups there were
no differences in clinicopathological or laboratory values at pres-
entation except for the presence of metastatic disease at diagnosis
(Table 1).
Twenty-four patients (48%) had metastatic disease at presen-
tation with 0 Surgical patients (0%), 11 Chemo/Embol patients
(61%), and 13 (52%) Observation patients possessing metastasis
at the time of diagnosis (P = 0.02; Table 1). Four patients (8%) had
multiple sites of metastatic disease at the time of presentation. The
majority of patients presented with bilateral hepatic disease at the
time of presentation (n = 38, 76%) and 53% (n = 20) of these
patients had evidence of metastatic disease, compared with only
33% (n = 4) of patients with unilateral hepatic disease presenting
with evidence of metastasis. The most common site of metastasis
was lung (n = 21, 88%), followed by bone (n = 5, 21%).
Patients were more likely to be referred to medical oncology
(n = 37, 74%) than to surgery (n = 13, 26%; P < 0.01) for their
initial treatment. Those who were initially referred to the medical
oncology service were more likely to undergo initial Chemo/
Embol treatment (n = 16, 43%) or initial Observation (n = 21,
57%) than to be subsequently referred to surgery for their initial
treatment (n = 0, 0%; P < 0.01). Conversely, there was no differ-
ence in initial treatment regimens (P = 0.2) for those patients who
were referred to the surgical service for initial treatment recom-
mendations as 7 patients (54%) underwent Surgery, 2 patients
(15%) were referred for Chemo/Embol treatment and 4 patients
(31%) underwent Observation.
Initial treatment cohorts
Figure 1 demonstrates the entire cohort (n = 50) of patients diag-
nosed with HEHE based upon the initial treatment regimen. After
the diagnosis of HEHE, 7 patients (14%) comprised the Surgical
Group, 18 patients (36%) the Chemo/Embol group and 25
patients (50%) were in the Observation group. There was no
statistical difference in the median time from initial diagnosis to
initial treatment between patients in the Surgical group [39 days
(range 24–46 days)] compared with the Chemo/Embol group [36
days (range 0–79 days), P = 0.7].
Cohort treatment history
Initial surgical cohort
Seven patients (14%) were evaluated and had surgery as their
initial treatment for HEHE (Fig. 1). There was no peri-operative
(< 30 day) mortality in the entire cohort. Only one patient (10%)
recurred during follow-up and the patient subsequently under-
went orthotopic liver transplantation but developed additional
recurrent disease in the transplanted liver as well as lung metas-
tases. Systemic interferon therapy was given to this patient for 3
months but discontinued secondary to rejection of the trans-
planted liver and the patient subsequently died. This is the only
patient in the initial Surgery cohort who was later treated with a
Chemo/Embol modality (in this case an immunomodulating
agent). No patient in the initial Surgery cohort was ever given
systemic chemotherapy.
At last follow-up, for the cohort of 7 patients treated initially
with surgery, 3 patients (43%) were alive without evidence of
disease, 2 (29%) were alive with disease, 1 patient (14%) died of
disease and 1 patient (14%) was without disease but died of non-
related causes (Table 2). Of the 11 patients who were treated with
surgery at any time during their disease course, 1 patient (9%)
developed lung metastases, and 2 patients (18%) developed a local
recurrence which were subsequently treated with radiofrequency
ablation and orthotopic transplantation, respectively.
Initial chemo/embol cohort
Eighteen (36%) patients were initially treated with non-surgical
interventions after their diagnosis of HEHE (Fig. 1). Seven
patients were given various regimens of chemotherapy and one
patient received chemotherapy (paclitaxel) in combination with
bevacizumab. Five were given biological agents including inter-
feron (n = 4) or tumour necrosis factor (n = 1), 2 patients were
treated with anti-angiogenics including celecoxib (n = 1), thalido-
mide (n = 1), and the aforementioned patient who received
bevacizumab in combination with paclitaxel. Three patients
were treated with embolization of the tumour. Eleven patients
(55%) had a treatment change or addition from their initial
chemotherapy/embolization management, which was as a result
of tumour progression or toxicity of the original therapy. Three
patients were placed on chemotherapy or biologics, two patients
had tumor embolization performed, two patients underwent
orthotopic liver transplantation, one patient was switched to
interferon while another had a dose increase, one patient was
changed to celecoxib and one patient had external beam radiation
to dermal metastases. No patient treated initially or secondarily
with chemotherapy/embolization was rendered free of disease.
Of the 18 patients in the initial Chemo/Embol group, only 2
(11%) were free of disease at last follow-up both having under-
gone salvage orthotopic liver transplantation after progression on
initial medical therapies. Of the remaining patients who were
initially treated in the Chemo/Embol group, 9 patients (50%)
were alive with disease and 7 patients (39%) died of their disease
at last follow-up (Table 2).
Initial observation cohort
Upon initial diagnosis of HEHE, 25 (50%) patients underwent
observation only (Fig. 1). Fourteen of these patients (56%) had
progression of disease during this observation period. One patient
had rapid progression and died, the remaining 13 patients were
switched to either Surgical or Chemo/Embol treatment. This
included celecoxib (n = 6, 24%), interventional techniques includ-
ing radiofrequency ablation, embolization, or intratumoural
injection (n = 3, 12%), chemotherapy (n = 1, 4%), interferon (n =
1, 4%) and surgical resection (n = 2, 8%). The median period of
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Table 1 Cohort demographics and clinical parameters by initial treatment regimen
Entire cohort Surgical Chemo/Embol Observation
n = 50 n = 7 (14) n = 18 (36) n = 25 (50) p
Gender, n (%)
Male 17 (34) 3 (43) 6 (33) 8 (32) NS (0.9)
Female 33 (66) 4 (57) 12 (67) 17 (68
Age at Diagnosis, years
Median (Range) 46 (18–92) 33 (18–46) 51 (22–72) 48 (18–92) NS (0.09)
Age at Presentation to MDACC, years
Median (Range) 46 (18–92) 34 (18–46) 52 (22–72) 48 (18–92) NS (0.09)
BMI, kg/m2
Median (Range) 26 (15–81) 25 (19–37) 25 (15–38) 26 (20–81) NS (0.6)
Presenting symptom, n (%)
Abnormal LFTs 6 (12) 1 (14) 2 (11) 3 (12) NS (0.8)
Abnormal imaging 8 (16) 1 (14) 2 (11) 5 (20)
Fatigue 2 (4) 0 (0) 1 (6) 1 (4)
Pain 28 (56) 5 (71) 10 (56) 13 (52)
Weight loss 2 (4) 0 (0) 2 (11) 0 (0)
Other 4 (8) 0 (0) 1 (6) 3 (12)
Albumin (g/dl)
Median (range) 3.95 (2.8–5.2) 4.6 (2.8–5.2) 3.9 (2.9–5) 4.05 (3–4.6) NS (0.24)
AST (IU/l)
Median (range) 24 (12–105) 16 (12–20) 23 (15–105) 27 (15–93) NS (0.08)
ALT (IU/l)
Median (range) 32 (10–140) 28.5 (12–113) 41 (10–129) 30 (10–140) NS (0.35)
Alkaline phosphatase (IU/l)
Median (range) 114 (55–877) 130.5 (70–295) 121 (79–877) 93 (55–842) NS (0.15)
Total bilirubin (mg/dl)
Median (range) 0.5 (0.2–3.9) 0.55 (0.3–1.5) 0.45 (0.2–2) 0.6 (0.3–3.9) NS (0.9)
Intrahepatic distribution, n (%)
Unilateral 12 (24) 3 (43) 2 (11) 7 (28) NS (0.2)
Bilateral 38 (76) 4 (57) 16 (89) 18 (72)
Disease pattern, n (%)
Nodular 32 (64) 4 (57) 13 (72) 15 (60) NS (0.7)
Diffuse 18 (36) 3 (43) 5 (28) 10 (40)
Total tumour nodules, no.
Median (range) 8 (1–59) 8 (1–23) 11 (8–28) 7 (1–59) NS (0.2)
Largest tumour nodule (cm)
Median (range) 4 (1.5–12.9) 3.6 (3–11) 4 (2–9.8) 4 (1.5–12.9) NS (0.9)
Metastasis, n (%)
No 26 (52) 7 (100) 7 (39) 12 (48) 0.02
Yes 24 (48) 0 (0) 11 (61) 13 (52)
Time from Dx to 1st Tx, non-obs, days
Median (range) 39 (0–79) 39 (24–46) 36 (0–79) N/A NS (0.7)
Time between 1st and 2nd Tx, days
Median (range) 328 (0–3630) 585 (585) 173 (0–2705) 379 (71–3630) NS (0.43)
All laboratory values indicate measurements at the time of diagnosis. BMI, Body Mass Index; LFTs, Liver Function Tests; CT, Computed Tomography;
AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; LDH, Lactate Dehydrogenase; Dx, Diagnosis; Tx, Treatment; Non-Obs, Non-
Observational Cohort.
680 HPB
HPB 2014, 16, 677–685 © 2013 International Hepato-Pancreato-Biliary Association
observation prior to subsequent chemotherapy/embolization or
surgical treatment for tumour progression was 322 days (range
114–3630).
For those individuals who were initially observed, only one
patient was without evidence of disease at last follow-up; a patient
who later underwent a left hepatectomy for disease progression
while on observation. Otherwise, the majority of patients who
were initially observed were alive with stable disease (Table 2).
Survival
The 5-year survival rate for the entire cohort from the time of
diagnosis was 73% with a median follow-up of 51 months (range
1–322). There were no clinicopathological predictors of TTP or
OS on univariate analysis except for age > 45 years and the number
of tumour nodules > 8 being a predictor of OS on univariate
analysis only (HR 3, CI 1.1–7.9, P = 0.05; HR 4.1, CI 1.2–13.9, P =
0.02, respectively). There was no statistically significant difference
in the 5-year survival rates based on the initial treatment regimen
comparing the Surgery (83%), Chemo/Embol (71%), and Obser-
vation (72%) cohorts (Surgery vs. Chemo/Embol, P = 0.9;
Chemo/Embol versus Observation, P = 0.8; Surgery vs. Observa-
tion, P = 0.9; Table 3).
To determine if increased tumour burden or the presence of
metastatic disease may play a role in the survival of patients diag-
nosed with HEHE, survival analysis was performed on these
cohorts. Based on the anatomic distribution of disease, there was
no statistical difference in the 5-year survival rates between
patients who presented with unilateral disease compared with
bilateral disease (51% versus 81%, respectively; P = 0.1), nor in
patients with localized (hepatic only) disease at the time of diag-
nosis versus metastatic disease (69% vs. 78%, respectively; P =
0.7). Finally, there was no difference in 5-year survival based upon
the disease pattern (nodular versus diffuse) at diagnosis for the
entire cohort or when stratified based on the initial treatment
regimen. However, patients with greater than eight hepatic
tumour nodules had a worse 5-year survival than those who did
not when evaluating the entire cohort (52% versus 87%, respec-
tively; P = 0.05; Table 3) but there was no significant difference
when stratified based on the initial treatment regimen.
Interestingly, patients who received chemotherapy at any time
during their disease course had a worse 5-year survival than those
who did not (44% versus 83%, respectively; P = 0.02; Table 3). This
was in spite of similar intrahepatic disease burden as there was no
statistical difference between patients with unilateral or bilateral
hepatic disease at presentation who received chemotherapy and
those who did not (P = 0.5). As expected, patients who presented
with metastatic disease were more likely to receive chemotherapy
than those who did not (P = 0.03) but even patients who presented
Diagnosis of HEHE
(50)
Surgery
(7)
Observation
(25)
Chemo/Embol
(18)
Embolization
(3)
Anti-Angiogenic
(3)
Biological
(5)
Chemo
(5)
Orthotopic
Transplantation
(1)
No Recurrence
(6)
No Progression
(11)
Progression
(14)
No Progression
(6)
Progression
(12)
Recurrence
(1)
Minor
Hepatectomy
(1)
Major
Hepatectomy
(5)
Figure 1 Flow diagram of the initial treatment regimen for the cohort of patients diagnosed with hepatic epithelial haemangioendothelioma
(HEHE)
Figure 2 Example of a patient who was a poor medical candidate for
a surgical resection and was initially treated with observation only for
a diagnosis of hepatic epithelial haemangioendothelioma (HEHE).
Within a 5-year observational period, between 2001 (a) and 2006 (b),
there was spontaneous involution and regression of the tumour
without any treatment. This patient went on to have stable disease
and received no specific treatment for HEHE
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with metastatic disease and received chemotherapy at any time
during their disease course had a worse 5-year survival than
patients with metastatic disease who never received chemotherapy
(44% versus 100%, respectively; P < 0.01). Based on univariate
analysis, there were no factors predictive of TTP. However, treat-
ment with chemotherapy at any time was an independent predictor
of decreased OS (HR 3.1 [CI 0.9–10.7], P = 0.02). However, based
on multivariate regression, treatment with chemotherapy was not
predictive of OS (HR 2.5 [CI 0.92–7], P = 0.07).
Discussion
This study identified and confirmed several important issues
regarding risk factors and outcomes for patients with HEHE.
The data confirm that HEHE is more frequent in women and
patients typically present in the 4th decade of life.19 The overall
rate of HEHE metastases was 48% at the time of diagnosis in
this cohort of patients, which is consistent with previously pub-
lished initial staging information. Other previous studies have
associated the use of oral contraceptive, hepatitis infection and
liver trauma with HEHE.1,3,13,19 Only five patients in our study
reported oral contraceptive use and only three patients had
known hepatitis B infection. This is likely secondary to limita-
tions in this retrospective study as not all patients were assessed
for hepatitis serology nor inquired on oral contraceptive use.
The possible aetiology of HEHE, therefore, remains unclear
given the rarity of the disease and, often, the misclassification of
the tumour.
Surgical Candidate?
(Resection or Transplantation)
No Yes
No
Observe
Progression? Progression?
Yes
Observe
Resection vs.
Transplantation
Resection vs.
Transplantation
Surgical Candidate?
(Resection or Transplantation)
Chemo/Embol
Therapies
Continued
Observation
No YesYesNo
Figure 3 Treatment algorithm for patients diagnosed with hepatic epithelial haemangioendothelioma (HEHE) initially based on their surgical
candidacy. Surgical candidacy depends upon the intrahepatic distribution of tumours such that a patient may undergo a hepatectomy with
adequate functional liver reserve for disease clearance versus liver transplantation. Additionally, the medical fitness of a patient to undergo
a hepatectomy or transplantation plays a large role in surgical candidacy. Regardless, patients should undergo an initial period of observation
for approximately 6–12 months prior to treatment initiation
Table 2 Status of patients at last follow-up based on the initial treatment regimen
Disease Status Entire cohort Surgical Chemo/Embol Observation
(%) n = 50 n = 7 (14) n = 18 (36) n = 25 (50)
NED 6 (12) 3 (43) 2 (11) 1 (4)
AWD 30 (60) 2 (29) 9 (50) 19 (76)
DWD 13 (26) 1 (14) 7 (39) 5 (20)
DOC 1 (2) 1 (14) 0 (0) 0 (0)
NED, No Evidence of Disease; AWD, Alive With Disease; DWD, Died With Disease; DOC, Died Other Causes.
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The definitive diagnosis of HEHE can only be made by
histopathological review of tissue with the presence of character-
istic clusters of epithelioid appearing cells in the sinusoids and
smalls veins of the liver. HEHE is often misdiagnosed for
cholangiocarcinoma, and fibrolamellar hepatocellular carcinoma.
However, immunohistochemical staining confirms the correct
diagnosis with cells staining positive for the endothelial cell
markers FVIII-related antigen, CD31 and CD34.20 Pathology
studies have described two distinct forms of HEHE: a nodular
type and a diffuse type. The early growth of HEHE is character-
ized by the nodular lesions that vary from 1 to 3 cm in size. As the
smaller lesions grow and coalesce, the lesions become extensive.
CT scans of these lesions demonstrate peripherally located low-
density nodules with capsular retraction and areas of calcification
can be seen within the lesions.21,22 Lesions can also contain
fibromyxoid stroma at the periphery and may explain why some
lesions spontaneously regress. The stroma may theoretically
restrict blood flow to the proliferating tumour cells, causing spon-
taneous regression even with no treatment (Fig. 2).
Although our analysis is one of the larger series to date for
patients with HEHE (Table 4), it is limited by a small and hetero-
geneous patient population and retrospective nature of the cohort
evaluation. In addition, as our institution is not a transplant
centre, our cohort lacked significant patients who underwent liver
transplantation for initial treatment of HEHE which has been
shown to have favourable long-term outcomes.14–16 As such, one
surgical cohort was designed to evaluate its role in the initial
management of HEHE. The present series is unique in that com-
parisons were made between all treatments rendered, without
focusing on one particular treatment such as surgery, for example.
In spite of these limitations, the key finding of our study was the
spectrum of the observed natural history, with many patients
experiencing an indolent course, and even some patients demon-
strating stability of disease or spontaneous regression of tumours
without therapy (Fig. 2). Reflecting the tendency towards indo-
lence, the study patients demonstrated no difference in survival
based upon the treatment regimen initially utilized at diagnosis.
Although prior studies have demonstrated a survival difference
based on the disease pattern of nodular compared with diffuse, we
did not find such a survival difference in neither our entire cohort
nor when stratified based upon the initial treatment regimen.13
Literature has also suggested that tumours less than 10 cm are
more predictive of a favourable OS but this was not the case in our
cohort of patients and stratifying based on the median tumour
size of 4 cm in our cohort, there likewise was not a survival dif-
ference.13 However, the number of tumour nodules, in our cohort
greater than 8, as well as older age at diagnosis were both associ-
ated with a worse prognosis on univariate analysis, which cor-
roborates earlier studies.13,23 In addition, the analysis identified a
possible detrimental effect of chemotherapy in treating patients
with HEHE. Our data indicate that patients who received any
chemotherapy experienced a shorter 5-year survival, compared
with patients who never received systemic chemotherapy, in spite
of a similar intrahepatic and extrahepatic disease burden between
these two groups. This may be related to the fact that HEHE
represents part of a spectrum of disease from haemangioma to
haemangiosarcoma. In particular, those patients with biologically
indolent disease that is more representative of a haemangioma
may be better served by observation only, as the morbidity of
chemotherapy may be detrimental. Conversely, those patients
whose tumour biology reflects a more aggressive disease may
benefit from a surgical resection or transplantation and receive
little benefit from chemotherapeutic regimens, which have not
been proven successful with this disease. Although more patients
with metastatic disease at presentation were treated with chemo-
therapy, there was no difference in survival based on the presence
or absence of metastatic disease nor for patients with metastatic
disease based on treatment modality. This finding suggests that
either more aggressive tumour biology or simply lead-time bias
Table 3 Summary of the 5-year survival rates of patients diagnosed
with HEHE based on initial treatment and clinical factors
Cohort comparison 5-year survival (%) P
Entire cohort 73 N/A
Age at diagnosis, years
< 45 91 0.03
> 45 60
Initial treatment
Surgical 83 NS (0.9)a
Chemo/Embol 71 NS (0.8)b
Observation 72 NS (0.9)c
Hepatic disease
Unilobar 51 NS (0.1)
Bilobar 81
Disease pattern
Nodular 69 NS (0.6)
Diffuse 80
Total tumour nodules
<8 87 0.05
>8 52
Largest tumour size (cm)
<4 78 NS (0.7)
>4 68
Extrahepatic disease
No 64 NS (0.7)
Yes 78
Received chemotherapy
No 83 0.02
Yes 44
Summary of 5-year survival rates for patients diagnosed with HEHE
based on various cohort analysis. The comparison of 5-year survival
rates demonstrated no statistical difference when initial treatment
cohorts were compared [Surgical vs. Chemo/Embol (a), Chemo/Embol
vs. Observation (b), Surgical vs. Observation (c).
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impacts the prognosis of patients with metastatic disease but
should not necessarily be a contraindication to surgery.14,24 As
such, systemic chemotherapy is not mandatory and recent studies
have reported long-term survival with transplantation in patients
with metastatic disease.13,14,24
Our experience represents one of the largest cohorts with
HEHE in the literature to date and is unique in its evaluation of
various initial treatment regimens (Table 4). Institutional experi-
ence with this disease is variable because of the rarity of the
disease and a lack of treatment consensus in the medical commu-
nity. This is likewise demonstrated by the heterogeneous treat-
ment in our cohort. Even at our institution, the referral patterns
often dictated the eventual treatment initially rendered as patients
who were referred to the medical oncology service more often
initially underwent either Chemo/Embol treatment or Observa-
tion than Surgery. Although our survival analysis did not show a
statistical difference between patients who underwent Chemo/
Embol, Surgery or Observation, the survival of patients treated
with chemotherapy was decreased compared with those individ-
uals who were never treated with chemotherapy in spite of a
similar intrahepatic and extrahepatic disease burden. There were
no cases of Chemo/Embol patients being rendered free of disease,
as opposed to the surgically treated patients, and several patients
treated by Observation alone had appreciable long-term survival.
We therefore believe that patients diagnosed with HEHE, as
confirmed by biopsy and immunohistochemical positive staining
for endothelial markers, should undergo a period of observation
to assess disease biology (Fig. 3). In many cases, observation may
demonstrate stability or regression of disease without the need for
any intervention. Subsequently, patients with clearly resectable
disease, progression of disease, or symptomatology even after a
period of observation should be offered a surgical resection if
the disease remains anatomically resectable. Patients with large
volume disease in which a resection is not feasible should be
referred for a liver transplantation. Additionally, metastatic
disease should not preclude a resection or transplantation as these
patients have a similar survival to patients with localized disease
and long-term survival after surgical treatment has been reported.
Conversely, Chemo/Embol treatment is reserved for patients with
large-volume disseminated and progressive disease or for those
who are not medically fit to undergo a surgical resection or trans-
plantation. Observation is typically elected for patients who have
multifocal but low volume disease and may undergo a future
resection with stable disease. In addition, those who are not medi-
cally fit for a resection, transplantation or Chem/Embol treat-
ments should undergo observation.
In summary, the clinical course in patients with hepatic
epithelioid haemangioendothelioma is typically indolent.Whereas
favourable outcomes from surgery and transplantation are becom-
ing established, outcomes from other therapeutic options remain
less clear and patient selection and overall treatment strategies are
lacking. Patients with HEHE should be referred to surgery to
Table 4 Comparison of contemporary literature involving hepatic epithelial haemangioendothelioma
Author Year Study Type Treatment Cohort (n) 5-year survival
Mehrabi18 2006 Meta Combo 253 41
LT 55
LR 75
Chemo/Embol 30
Obs 5
Lerut14 2007 Retro Combo 59 83
LT 80
Grotz13 2010 Retro Combo 30 64
LT 73
LR 86
Chemo/Embol+Obs 29
Wang23 2012 Retro Combo 33 73a
LR 74a
Chemo/Embol 82a
Thomas 2013 Retro Combo 50 73
(Present Series) Surgical 83
Chemo/Embol 71
Observation 72
Study type refers to meta-analysis (Meta) or retrospective study (Retro). All studies were combination (Combo) studies in which patient cohorts
underwent various treatments including liver transplantation (LT), liver resection (LR), chemotherapy and/or interventional radiologic treatments
(Chemo/Embol), or observation (Obs). All studies represent 5-year survival rates except for the study by Wang et al. which represents 3-year survival
(a).
684 HPB
HPB 2014, 16, 677–685 © 2013 International Hepato-Pancreato-Biliary Association
determine resectability or candidacy for transplantation and pre-
sented in a multidisciplinary conference. Present data suggest that
observation of clinical behaviour may be a key step in management
for patients with HEHE, and as such should be considered in
a clinical trial design as future prospective registry or multi-
institutional studies, including transplant centres, are developed to
clarify prognostic factors and treatment sequencing options for
patients with this rare but intriguing disease.
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